The number of TNBC patients in India is highest in the world. It has been widely seen that the clinical behavior of the disease and response to neo-adjuvant chemotherapy is very variable in TNBC patients due to disease heterogeneity and even ethnicity driven genetic make-up of the population. However, we lacking with appropriate cellular and animal models that can help us to understand the molecular factors that determine clinical progression and therapeutic response in Indian population.
At this front, our group has initiated efforts to build tumor originated cellular models and pre-clinical patient derived xenograft (PDX) models form Indian patients that can promote the understanding of TNBC pathology and molecular landscapes to the disease in Indian sub-continent. These models will help us to understand the nature of disease in our population.